-
公开(公告)号：US20220324872A1
公开(公告)日：2022-10-13
申请号：US17841138
申请日：2022-06-15
Applicant: Pfizer Inc.
Inventor： Douglas Carl Behenna , Ping Chen , Kevin Daniel Freeman-Cook , Robert Louis Hoffman , Mehran Jalaie , Asako Nagata , Sajiv Krishnan Nair , Sacha Ninkovic , Martha Alicia Ornelas , Cynthia Louise Palmer , Eugene Yuanjin Rui
IPC: C07D487/04 , C07D471/04 , C07D401/14
Abstract: This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R2, R2A, R2B, R3, R4, R5A, R5B, R6, R7, R8, R9, p, q and r are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
-
公开(公告)号：US11203594B2
公开(公告)日：2021-12-21
申请号：US16849329
申请日：2020-04-15
Applicant: Pfizer Inc.
Inventor： Samit Kumar Bhattacharya , Douglas Carl Behenna , Kimberly O. Cameron , Ping Chen , John M. Curto , Kevin Daniel Freeman-Cook , Mehran Jalaie , Robert Steven Kania , Yajing Lian , Sajiv Krishnan Nair , Cynthia Louise Palmer , Martin Youngjin Pettersson , Eugene Yuanjin Rui , Matthew Sammons , Qingyi Yang , Liying Zhang
IPC: C07D471/04 , A61P9/12
Abstract: This invention relates to compounds of general Formula I in which A, R1, R2, R3 and R4 are as defined herein, and the pharmaceutically acceptable salts thereof; to pharmaceutical compositions comprising such compounds and salts; to methods of using such compounds, salts and compositions for treating pulmonary hypertension and related diseases, like pulmonary arterial hypertension; to methods of using such compounds, salts and compositions for treating abnormal cell growth, such as cancer; and to processes to make such compounds, salts and compositions.
-
公开(公告)号：US20190135817A1
公开(公告)日：2019-05-09
申请号：US16251032
申请日：2019-01-17
Applicant: Pfizer Inc.
Inventor： Douglas Carl Behenna , Ping Chen , Kevin Daniel Freeman-Cook , Robert Louis Hoffman , Mehran Jalaie , Asako Nagata , Sajiv Krishnan Nair , Sacha Ninkovic , Martha Alicia Ornelas , Cynthia Louise Palmer , Eugene Yuanjin Rui
IPC: C07D487/04 , C07D401/14 , C07D471/04
Abstract: This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R2 , R2A , R2B, R3, R4, R5A, R5B, R6, R7, R8, R9, p, q and r are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
-
公开(公告)号：US09133215B2
公开(公告)日：2015-09-15
申请号：US14156144
申请日：2014-01-15
Applicant: PFIZER INC.
Inventor： Simon Bailey , Benjamin Joseph Burke , Michael Raymond Collins , Jingrong Jean Cui , Judith Gail Deal , Robert Louis Hoffman , Qinhua Huang , Ted William Johnson , Robert Steven Kania , John Charles Kath , Phuong Thi Quy Le , Michele Ann McTigue , Cynthia Louise Palmer , Paul Francis Richardson , Neal William Sach
IPC: C07D273/02 , C07D413/04 , C07D413/14 , C07D491/08 , C07D491/18 , C07D498/08 , C07D498/18 , C07D498/22 , C07D513/18
CPC classification number: C07D498/08 , C07D273/02 , C07D413/04 , C07D413/14 , C07D491/08 , C07D491/18 , C07D498/18 , C07D498/22 , C07D513/18
Abstract: The invention relates to compounds of formula (Φ) as further defined herein and to the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to the uses thereof. The compounds and salts of the present invention inhibit anaplastic lymphoma kinase (ALK) and/or EML4-ALK and are useful for treating or ameliorating abnormal cell proliferative disorders, such as cancer.
Abstract translation: 本发明涉及本文进一步定义的式（Φ）化合物及其药学上可接受的盐，涉及包含这些化合物和盐的药物组合物及其用途。 本发明的化合物和盐抑制间变性淋巴瘤激酶（ALK）和/或EML4-ALK，并且可用于治疗或改善异常细胞增殖性疾病如癌症。
-
公开(公告)号：US20130252961A1
公开(公告)日：2013-09-26
申请号：US13786106
申请日：2013-03-05
Applicant: PFIZER INC.
Inventor： Simon BAILEY , Benjamin Joseph Burke , Michael Raymond Collins , Jingrong Jean Cui , Judith Gail Deal , Robert Louis Hoffman , Qinhua Huang , Ted William Johnson , Robert Steven Kania , John Charles Kath , Phuong Thi Quy Le , Michele Ann McTigue , Cynthia Louise Palmer , Paul Francis Richardson , Neal William Sach
IPC: C07D498/08 , C07D513/18 , C07D498/22 , C07D498/18 , C07D491/18
CPC classification number: C07D498/08 , C07D273/02 , C07D413/04 , C07D413/14 , C07D491/08 , C07D491/18 , C07D498/18 , C07D498/22 , C07D513/18
Abstract: The invention relates to compounds of formula (Φ) as further defined herein and to the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to the uses thereof. The compounds and salts of the present invention inhibit anaplastic lymphoma kinase (ALK) and/or EML4-ALK and are useful for treating or ameliorating abnormal cell proliferative disorders, such as cancer.
Abstract translation: 本发明涉及本文进一步定义的式（Phi）化合物及其药学上可接受的盐，涉及包含这些化合物和盐的药物组合物及其用途。 本发明的化合物和盐抑制间变性淋巴瘤激酶（ALK）和/或EML4-ALK，并且可用于治疗或改善异常细胞增殖性疾病如癌症。
-
Patent Agency Ranking
公开(公告)号：US20220089580A1
公开(公告)日：2022-03-24
申请号：US17544303
申请日：2021-12-07
Applicant: Pfizer Inc.
Inventor： Ping Chen , Sujin Cho-Schultz , Judith Gail Deal , Gary Michael Gallego , Mehran Jalaie , Robert Steven Kania , Sajiv Krishnan Nair , Sacha Ninkovic , Suvi Tuula Marjukka Orr , Cynthia Louise Palmer
IPC: C07D407/14 , C07D401/14 , C07D487/04 , C07D498/04
Abstract: This invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt thereof, in which R-groups R1 to R23, A, Q, U, V, W, X, Y, Z, n, p and q are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject.
-
公开(公告)号：US20200331909A1
公开(公告)日：2020-10-22
申请号：US16849329
申请日：2020-04-15
Applicant: Pfizer Inc.
Inventor： Samit Kumar Bhattacharya , Douglas Carl Behenna , Kimberly O. Cameron , Ping Chen , John M. Curto , Kevin Daniel Freeman-Cook , Mehran Jalaie , Robert Steven Kania , Yajing Lian , Sajiv Krishnan Nair , Cynthia Louise Palmer , Martin Youngjin Pettersson , Eugene Yuanjin Rui , Matthew Sammons , Qingyi Yang , Liying Zhang
IPC: C07D471/04 , A61P9/12
Abstract: This invention relates to compounds of general Formula I in which A, R1, R2, R3 and R4 are as defined herein, and the pharmaceutically acceptable salts thereof; to pharmaceutical compositions comprising such compounds and salts; to methods of using such compounds, salts and compositions for treating pulmonary hypertension and related diseases, like pulmonary arterial hypertension; to methods of using such compounds, salts and compositions for treating abnormal cell growth, such as cancer; and to processes to make such compounds, salts and compositions.
-
公开(公告)号：US20180044344A1
公开(公告)日：2018-02-15
申请号：US15664265
申请日：2017-07-31
Applicant: Pfizer Inc.
Inventor： Douglas Carl Behenna , Ping Chen , Kevin Daniel Freeman-Cook , Robert Louis Hoffman , Mehran Jalaie , Asako Nagata , Sajiv Krishnan Nair , Sacha Ninkovic , Martha Alicia Ornelas , Cynthia Louise Palmer , Eugene Yuanjin Rui
IPC: C07D487/04 , C07D401/14
CPC classification number: C07D487/04 , C07D401/14 , C07D471/04
Abstract: This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R2, R2A, R2B, R3, R4, R5A, R5B, R6, R7, R8, R9, p, q and r are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
-
公开(公告)号：US10800783B2
公开(公告)日：2020-10-13
申请号：US16251032
申请日：2019-01-17
Applicant: Pfizer Inc.
Inventor： Douglas Carl Behenna , Ping Chen , Kevin Daniel Freeman-Cook , Robert Louis Hoffman , Mehran Jalaie , Asako Nagata , Sajiv Krishnan Nair , Sacha Ninkovic , Martha Alicia Ornelas , Cynthia Louise Palmer , Eugene Yuanjin Rui
IPC: A61K31/519 , A61K31/4375 , A61K31/4545 , C07D487/04 , C07D401/12 , C07D471/04 , C07D401/14
Abstract: This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R2, R2A, R2B, R3, R4, R5A, R5B, R6, R7, R8, R9, p, q and r are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
-
公开(公告)号：US08680111B2
公开(公告)日：2014-03-25
申请号：US13786106
申请日：2013-03-05
Applicant: Pfizer Inc.
Inventor： Simon Bailey , Benjamin Joseph Burke , Michael Raymond Collins , Jingrong Jean Cui , Judith Gail Deal , Robert Louis Hoffman , Qinhua Huang , Ted William Johnson , Robert Steven Kania , John Charles Kath , Phuong Thi Quy Le , Michele Ann McTigue , Cynthia Louise Palmer , Paul Francis Richardson , Neal William Sach
IPC: A01N43/42 , A61K31/44 , A01N43/02 , A61K31/335 , C07D471/00 , C07D491/00 , C07D498/00 , C07D513/00 , C07D515/00 , C07D313/00
CPC classification number: C07D498/08 , C07D273/02 , C07D413/04 , C07D413/14 , C07D491/08 , C07D491/18 , C07D498/18 , C07D498/22 , C07D513/18
Abstract: The invention relates to compounds of formula (Φ) as further defined herein and to the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to the uses thereof. The compounds and salts of the present invention inhibit anaplastic lymphoma kinase (ALK) and/or EML4-ALK and are useful for treating or ameliorating abnormal cell proliferative disorders, such as cancer.
Abstract translation: 本发明涉及本文进一步定义的式（Φ）化合物及其药学上可接受的盐，涉及包含这些化合物和盐的药物组合物及其用途。 本发明的化合物和盐抑制间变性淋巴瘤激酶（ALK）和/或EML4-ALK，并且可用于治疗或改善异常细胞增殖性疾病如癌症。
-
-
-
-
-
-
-
-
-
Search Results
14
records
(took 0.03 seconds)
